You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨康希諾生物(06185.HK)高開7.66% Ad5載體COVID-19疫苗接種後28天可耐受 並具有免疫原性
格隆匯 05-25 09:23
格隆匯5月25日丨康希諾生物(06185.HK)逆勢高開7.66%,報239港元,盤前成交2629萬港元,總市值532億港元。康希諾生物上週四曾創285.8港元的歷史高點後一度下挫約20%。康希諾生物今早在港交所公告發布重組新型冠狀病毒疫苗(腺病毒載體)臨牀試驗I期研究結果稱,Ad5載體COVID-19疫苗接種後28天可耐受,並具有免疫原性。健康成人中,對SARS-CoV-2的體液反應在接種後第28天達到峯值,接種後第14天產生快速的特異性T細胞反應。他們的發現表明,Ad5載體COVID-19疫苗值得進一步研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account